Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board

Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)

Today's Pre-Open Stock Movers

Eastman Kodak Company (NYSE: KODK) 72% HIGHER; news that federal regulators found no wrongdoing in getting a loan from the government.

Kura Oncology, Inc. (Nasdaq: KURA) 16.9% HIGHER; announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Companys oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML).

Matinas BioPharma Holdings, Inc. (NYSE:... More

Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to collaborate with the... More

Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the interim analysis of ZUMA-12, a multicenter, open-label, single-arm Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). After a single infusion of Yescarta, 85 percent of patients achieved a response (n=27 evaluable for efficacy), including 74 percent of patients with a complete response. The data were presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract #405).

Despite well-established standard treatment regimens in newly diagnosed large B-cell lymphoma, patients with... More

Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Magrolimab is an investigational, potential first-in-class, anti-CD47 monoclonal antibody being studied in previously untreated acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy, including patients with TP53-mutant AML. The study continues to demonstrate high response rates with magrolimab in combination with azacitidine, with an overall response rate of 63% (n=27/43) among the total patient population and 69% (n=20/29) in TP53-mutant patients. The data were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and... More